Summary Chromosomal aberrations of 20 stage 4s neuroblastomas were analysed by comparative genomic hybridization (CGH). In a subset of 13/20 tumours, telomerase activity was evaluated by the telomeric repeat amplification protocol (TRAP). The CGH data were compared with the CGH results of ten stage 1 and 2 (stage 1/2) and 22 stage 3 and 4 (stage 3/4) neuroblastomas. A total of 17/20 stage 4s neuroblastomas did not progress clinically, whereas tumour progression with lethal outcome occurred in 3/20 cases. The CGH data of clinically non-progressing stage 4s tumours revealed a high rate of whole-chromosome aberrations (73.4%) with an overrepresentation of mainly chromosomes 2, 6, 7, 12, 13, 17, 18 and an underrepresentation of mainly chromosomes 3, 4, 11, 14. MYCN amplification or lp deletion was observed in only 1/27 or 2/17 clinically non-progressing stage 4s tumours respectively, whereas all three progressive stage 4s neuroblastomas showed MYCN amplification, 1 p deletion and, in 2/3 cases, distal 1 7q gains. Except for one case, telomerase activity was not observed in non-progressing stage 4s neuroblastomas. In contrast, 4s tumours with lethal outcome revealed elevated telomerase activity levels. Our data suggest that stage 4s neuroblastomas belong to two biologically different groups, one of which displays the genetic features of localized stage 1/2 tumours, whereas the other mimics advanced stage 3/4 neuroblastomas.
Neuroblastoma, one of the most common solid tumours in childhood, varies widely in clinical behaviour, ranging from differentiation or spontaneous regression to malignant progression with lethal outcome. The extreme heterogeneity of neuroblastoma is best reflected in the clinical subgroup of 4s tumours. According to the revised international staging system, stage 4s ('s' for special) is restricted to neuroblastoma patients (patient age < 1 year) with tumour distribution in the liver, skin and/or bone marrow (Brodeur et al, 1993) . Whereas most 4s neuroblastomas are known to undergo spontaneous regression independently of anti-cancer therapies, some tumours later progress to stage 4 tumours (Bourhis et al, 1991; Wilson et al 1991) . In advanced neuroblastomas of the clinical stages 3/4, lp deletion and MYCN amplification were shown to be the most important prognostic indicators. In contrast to stage 3/4 tumours, genetic data on stage 4s neuroblastomas are scarce, although they represent as many as 10% of neuroblastomas (Balaban and Gilbert, 1983; Hayashi et al, 1989) . Studies focusing on the prognostic value of lp deletion and MYCN amplification revealed contradictory results for the group of stage 4s neuroblastomas (Nakagawara et al, 1990; Bourhis et al, 1991; Tonini et al, 1997) . Because of the small number of cases studied, the genetic features of stage 4s neuroblastomas are by no means clear yet. The assessment of telomerase activity levels as markers of in vivo immortalization and metastatic potential has gained in importance Received 22 August 1997 Revised 26 November 1997 Accepted 5 December 1997 Correspondence to: C Brinkschmidt over recent years (Healy, 1995) . The data of a recent study by Hiyama et al (1995) have indicated a possible prognostic relevance of telomerase activity for neuroblastomas.
Recent studies, including a study from our own laboratory, have shown that comparative genomic hybridization (CGH), which was introduced by Kallioniemi et al (1992) , serves as an ideal method to give a comprehensive picture of the major genetic imbalances in clinically advanced neuroblastomas (Altura et al, 1997; Brinkschmidt et al, 1997; Lastowska et al, 1997; Plantaz et al, 1997) . In this retrospective study, we analysed 20 4s tumours in order to reveal currently unknown chromosomal alterations of this enigmatic subgroup of neuroblastoma. An analysis of telomerase activity was performed in 13/20 cases.
MATERIALS AND METHODS Patients
Snap-frozen specimens of 20 4s neuroblastomas (untreated primary tumours), obtained from paediatric hospitals participating in the German Neuroblastoma Trial, were analysed. The clinical characteristics with follow-up data as well as the MYCN status (studied by semiquantitative Southern blot hybridization) are listed in Table 1 . The CGH results were compared with CGH data of 22 clinically advanced neuroblastomas of stage 3/4 (medium age 47.3 months, range 10.9-95.7) and ten localized neuroblastomas of clinical stage 1/2 (medium age 16.9 months, range 0. 03-48.8) . CGH data of stage 1/2 and stage 3/4 tumours as well as 2/20 stage 4s tumours have already been reported (Brinkschmidt et al, 1997 (1993) . Briefly, tumour DNA was labelled with biotin-16-dUTP (Boehringer Mannheim) and reference DNA from a healthy male donor was labelled with digoxigenin-1 -dUTP (Boehringer Mannheim) in a standard nick translation reaction. The DNAase I concentration in the labelling reaction was adjusted in order to reveal an average fragment size of 500-1000 base pairs. The labelled DNA fragments were purified from remaining nucleotides by column chromatography (Sephadex-G50).
For CGH, 500 ng of tumour DNA, 300 ng of reference DNA and 30 .tg of human Cot 1 DNA (Gibco) were co-precipitated and redissolved in 10 pg of hybridization buffer. Denaturation of DNA (75°C for 5 min) was followed by a preannealing time of 45 min at 37°C. Target metaphase spreads (46,XY), which had been prepared following standard procedures, were denatured separately in 70% formamide/2xSSC for 2 min at 72°C. Hybridization was allowed to proceed for 3-4 days. A subset of experiments was performed on commercially available metaphase spreads (Vysis). The denaturation of these slides was performed according to the manufacturer's instructions.
Post-hybridization washes were carried out to a stringency of 50% formamide/2 x SSC at 45°C and 0.1 x SSC at 600C. Biotinylated and digoxigenated sequences were detected simultaneously, using avidin-FITC (Boehringer, 1:200) and antidigoxigenin-rhodamine (Boehringer, 1:40) . The slides were counterstained with DAPI and mounted in an antifade solution (Vectashield, Vector laboratories).
Microscopy and Digital Image Analysis
Separate digitized grey level images of DAPI, FITC and rhodamine fluorescence were taken with a charge coupled device (CCD) camera (Cohu 6X-924) connected to a Leica DMRBE microscope. The image processing was carried out by use of Applied Imaging Software. Average green-red ratios were calculated for each chromosome in 5-10 metaphases.
Statistical thresholds and controls
Chromosomal regions with CGH ratio profiles surpassing the 50% CGH thresholds (upper threshold 1.25, lower threshold 0.75) were defined as loci with copy number gains or losses. Based on experiments with normal control DNA, these thresholds have been proved to eliminate false-positive results. However, some tumours revealed significant shifts of the ratio profiles towards gains or losses not surpassing the 50% thresholds. As 50% thresholds were British Journal of Cancer (1998) 77(12), [2223] [2224] [2225] [2226] [2227] [2228] [2229] . designed for diploid tumours (du Manoir et al, 1995) , genetic imbalances of hyperdiploid tumours may be within these thresholds. Significant CGH ratio profile shifts within the 50% thresholds were therefore taken into account in our data analysis, on condition that the 95% confidence limits did not touch the central line of the balanced state. Genetic imbalances that most often met the latter criteria were represented by whole-chromosome abnormalities, which are frequently seen in hyperdiploid tumours. Previous reverse hybridization experiments confirmed the consistency of these aberrations. Moreover, significant CGH ratio profile shifts with 95% confidence limits that did not touch the central line were not observed in control hybridizations of differentially labelled normal DNA, which were included in each CGH experiment. Control hybridizations on target metaphase spreads purchased from Vysis occasionally revealed false-positive results simultaneously involving chromosomes lp, 16 and 19. Copy number abnormalities revealing this aberration pattern were therefore excluded from data analysis. As the tumour specimens and normal DNA were not sex matched, entire X and Y chromosomes were excluded.
Telomerase assay
Extracts of tissue specimens were prepared according to a modified Kim's procedure, as described elsewhere (Poremba et al, 1997) . Briefly, frozen tissue samples of approximately 50 mg were homogenized in 100 pl of CHAPS lysis buffer. After 30 min incubation on ice, the lysates were centrifuged at 12 500 g for 30 min at 4°C. The supernatant was frozen rapidly in liquid nitrogen and stored at -80°C. The concentration of protein was measured using the Coomassie Protein Assay Reagent (BioRad, USA) and adjusted to 2 ,ug 1.-'
For the in vitro detection of telomerase activity, a modified version of the TRAP assay was used (Poremba et al, 1997) . In brief, 1 gl of each tissue extract (containing 2 jig ml-' protein) was Figure 3 Example of a two-colour probe image (tumour labelled in green, reference DNA labelled in red) of a progressing stage 4s neuroblastoma characterized by high-level copy number increases at the MYCN locus (2p23-24) and losses of the distal part of chromosome 1 p. Right, the average CGH ratio profile of chromosome 1 and 2 with the 95% confidence limits. The black line on the ratio profile reflects a balanced state, whereas the first green and red lines represent the 50% thresholds (du Manoir et al 1995) cell line VH-64), heat-inactivated controls (telomerase-positive of amplification products, 1 gl of PCR product and 6.7 gl of control incubated at 94°C for 5 min before reaction) and a negative loading buffer (90% formamide, 10% dextran blue) were mixed control (CHAPS-lysis buffer instead of sample). For the analysis and denatured at 94°C for 5 min. Aliquots of 6 ,ul were loaded on British Journal of Cancer (1998) 77(12), [2223] [2224] [2225] [2226] [2227] [2228] [2229] to denaturing 8% polyacrylamide gels on an automated laser fluorescence sequencer (ALFexpress, Pharmacia, Freiburg, Germany) and subjected to electrophoresis. Fluorescence data were collected automatically and analysed by the Fragment Manager Program Version 1.02 (Pharmacia). Each fluorescent peak was quantified in terms of size (base pairs), peak height and peak area in relation to the positive telomerase control: no telomerase activity (-); low telomerase activity (<30% of positive control); intermediate telomerase activity (30-70% of positive control); high telomerase activity (>70% of positive control).
In order to minimize the possibility of false-negative results with a lack of or low telomerase activity owing to tissue degradation and necrosis, RNA derived from frozen sections was amplified by reverse-transcriptase PCR (rt-PCR) for f-actin as an indirect marker of tissue viability (Figure 1) . Briefly, a 495-bp fragment of the human ,-actin gene was amplified with primers 5'-CATGCCATCCTGCGTCTGGAC-3' and 5'-CACGGAGTA-CTTGCGCTCAGGAGG-3'. as described elsewhere (DockhornDworniczak et al, 1994) .
Loss of heterozygosity (LOH) study (detection of 1 p36 deletion)
Constitutional DNA isolated from blood mononuclear cells of 28/52 neuroblastoma patients was used as a control for interpreting LOH observed in the tumour tissue (9/20 4s cases; 3/10 stage 1/2 cases; 16/22 stage 3/4 cases). The loci D1S80 and D1S76 containing a variable number of tandem repeats (VNTR) were PCR amplified as detailed in Brinkschmidt et al (1997) . LOH study results of stage 3/4 and stage 1/2 cases as well as 2/20 stage 4s tumours have been reported before (Brinkschmidt et al, 1997) . CGH of 4s tumours and localized stage 1/2 tumours revealed a much higher percentage of chromosome abnormalities involving the entire chromosome length (stage 4s 73.4%, stage 1/2 78.7%) compared with advanced stage 3/4 tumours (36.2%), which were characterized by a high rate of segmental aberrations. There was a strong predeliction of certain chromosomes to be overrepresented (chromosomes 2, 6, 7, 12, 13, 17, 18) or underrepresented (chromosomes 3, 4, 11, 14) . As can be seen in Figure 2 , this pattern of whole-chromosome abnormalities occurred irrespective of the tumour stage.
The most frequent genetic aberration of all three groups detected by CGH was observed on chromosome 17 (stage 4s 80%, stage 1/2 80%, stage 3/4 77%). In contrast to stage 3/4 cases, chromosome 17 imbalances of non-progressing stage 4s and stage 1/2 tumours were mostly represented by whole-chromosome gains (stage 4s 75%, stage 1/2 87.5%, stage 3/4 11.8%). Distal 17q gains were observed in two out of three progressing 4s neuroblastomas (Table 1) . The Southern blot analysis of MYCN amplification was consistent with CGH data. Clinically progressing 4s neuroblastomas were uniformly characterized by MYCN amplification, lp deletion (Figure 3 ) and elevated telomerase activity levels (Table 1) . Apart from one case, which showed MYCN amplification, lp deletion and low telomerase activity (no. 8, Table 1 ), all other nonprogressing 4s neuroblastomas lacked telomerase activity. The average number of chromosomal aberrations in telomerase-positive cases was not significant compared with telomerase negative stage 4s neuroblastomas (telomerase positive cases, 5.25 aberrations per tumour, range 2-9; telomerase negative cases, 9.0 aberrations per tumour, range 0-15).
Apart from MYCN amplification, other regional high-level copy number increases were not detected in stage 4s tumours. High-level copy number increases at 2p 13-14 and 3q24-26, observed in two stage 4 neuroblastomas, have previously been described (Brinkschmidt et al, 1997) .
The LOH 1p36 study revealed allelic losses on distal minisatellite loci DIS80 and D1S76 in four cases (two cases of stage 4s, two cases of stage 3), all of which showed lp deletion in the CGH analysis. A total of 19/28 cases studied retained heterozygosity for both loci, whereas five cases were not informative. Except for one case, CGH results were consistent with LOH analysis.
DISCUSSION
Stage 4s neuroblastoma was originally defined to identify patients with an excellent prognosis irrespective of an obvious tumour spread at the time of diagnosis Evans et al, 1971 ). In the meantime, it has become evident that up to 25% of 4s neuroblastomas do, after all, show tumour progression (Suarez et al, 1991) . In our series, 3/20 4s neuroblastoma patients died of their disease. Compared with the non-progressing neuroblastomas, the tumours of these patients showed strikingly different biological characteristics.
These included MYCN amplification and lp deletion, the most powerful prognostic markers in advanced-stage neuroblastomas (Seeger et al, 1985; Christiansen and Lampert, 1988; Caron et al, 1996) , as well as 17q imbalances and telomerase activity.
Ever since the first description of MYCN amplification in a 4s neuroblastoma by Tonini et al (1987) , the usefulness of MYCN amplification and 1 p deletion as prognostic markers has been questioned for 4s neuroblastomas (Nakagawara et al, 1990; Tonini et al, 1997 ). Yet, all three fatal cases of our study showed MYCN amplification and lp deletion. These findings corroborate the strong predictive value of these markers for the clinical subgroup of stage 4s tumours, which has also been described by Ambros et al (1995) , Caron (1995) and Bourhis et al (1991) .
The reliability of CGH for the detection of Ip deletions has been contentious (Kallioniemi et al, 1994) . Recent studies with polymorphic markers as well as fluorescence in situ hybridization (FISH) studies have nevertheless confirmed CGH-detected lp deletions (Brinkschmidt et al, 1997; Lastowska et al, 1997) . In the present study, constitutional DNA was available for two out of four stage 4s
British Journal of Cancer (1998) 77(12), 2223-2229 cases with CGH-detected Ip deletion and MYCN amplification. As expected, LOH lp36 was observed in both cases.
Recently published CGH and FISH studies on neuroblastoma indicated that aberrations of chromosome 17 play a major role in the biology of these tumours (Brinkschmidt et al, 1997; Lastowska et al, 1997; Plantaz et al, 1997) . Distal chromosome 17q gains were shown to be characteristic of advanced stage 3/4 tumours (Meddeb et al, 1996) . In our series, distal chromosome 17q gains were accordingly observed in two out of three progressing stage 4s tumours, whereas the majority of non-progressing tumours (13/17 cases) revealed gains of the entire chromosome 17. Poor prognostic markers were detected in only 2/17 nonprogressing cases. One patient (no. 8, Table 1 ), still in remission 61 months after diagnosis, showed MYCN amplification, lp deletion and low-level telomerase activity. Owing to the initial detection of MYCN amplification, aggressive chemotherapy was performed, which may have improved the prognosis. The second patient (no. 1, Table 1 ), who experienced an inconspicuous 18-month follow-up period, showed lp deletion and a segmental distal 1 7q gain, but no MYCN amplification or telomerase activity. Therapy did not differ from the non-progressing tumour group. However, long-term observation of both patients will be vital for detecting possible deviations from the genetically inconspicuous patient group.
As regressing cells do not normally grow in culture, few cytogenetic data on 4s tumours are available. In short-term cell culture studies by Hayashi et al (1989) similar chromosomal aberration patterns were observed in five stage 4s neuroblastomas and 23 localized stage 1/2 neuroblastomas. This is in accordance with our data showing the same rates and patterns of whole-chromosome abnormalities for these tumour stages. Although the exact ploidy rates of tumours cannot be obtained by CGH, a high rate of wholechromosome abnormalities most possibly reflects relative losses or gains of entire chromosomes in hyperdiploid karyotypes. This hypothesis is consistent with our CGH data as well as those of Plantaz et al (1997) , which revealed a high rate of whole-chromosome abnormalities in non-progressing stage 4s and stage 1/2 tumours. These tumours have regularly been shown to be triploid in flow cytometric and FISH studies (Ambros et al, 1996) , whereas advanced stage 3/4 neuroblastomas are mostly diploid (Look et al, 1991) .
The whole-chromosome abnormalities observed in our study were not random. Notably, there was a strong predilection of certain chromosomes to be overrepresented (chromosomes 2, 6, 7, 12, 13, 17, 18) or underrepresented (chromosomes 3, 4, 11,14) . This predeliction was observed not only in stage 4s or localized stage 1/2 tumours, but also in the advanced stage 3/4 neuroblastomas. In their recently published CGH studies, Lastowska et al (1997) and Plantaz et al (1997) found almost the same pattern of whole-chromosome abnormalities irrespective of tumour stage. The resulting characteristic chromosomal pattern might be attributed to selective pressure as a result of gene function(s) on additional chromosomes that provide cells with these extra chromosomes with a growth advantage (Plantaz et al, 1997) .
Telomerase activity was absent in all 16/20 non-progressive 4s tumours. This corresponds to the data of Hiyama et al (1995) , who analysed the telomerase activity of 100 neuroblastomas (among them eight stage 4s tumours). Whereas in their study low-level telomerase activity was mostly restricted to favourable neuroblastomas, two out of three unfavourable 4s tumours of our series exhibited low telomerase activity. We observed high telomerase activity in only one progressive tumour. In contrast to Hiyama' 
